

**(19) AUSTRALIAN PATENT OFFICE**

(54) Title  
Nucleic acid sequence and protein in addition to polypeptides coding for mannitol-dehydrogenases or parts thereof and the production and use thereof in diagnosis and therapy

(51)<sup>6</sup> International Patent Classification(s)  
**C12N** 15/09 (2006.01) 20060101ALI2006031  
**A61K** 39/00 (2006.01) 08MJJP **C12N**  
**A61K** 39/35 (2006.01) 1/19  
**A61P** 37/08 (2006.01) 20060101ALI2006031  
**C12N** 1/19 (2006.01) 08MJJP **C12N**  
**C12N** 1/21 (2006.01) 1/21  
**C12N** 9/04 (2006.01) 20060101ALI2006031  
**C12Q** 1/32 (2006.01) 08MJJP **C12N**  
**C12Q** 1/68 (2006.01) 9/04  
**C12R** 1/84 (2006.01) 20060101ALI2005100  
C12N 15/09 8BMEP **C12Q**  
20060101AFI2006031 1/32  
08MJJP **A61K** 20060101ALI2005100  
39/00 8BMEP **C12Q**  
20060101ALI2006031 1/68  
08MJJP **A61K** 20060101ALN200510  
39/35 08BMEP **C12R**  
20060101ALI2006031 1/84  
08MJJP **A61P** 20060101ALN200603  
37/08 10BMJP  
PCT/EP03/02873

(21) Application No: 2003219084

(22) Application Date: 2003 .03 .19

(87) WIPO No: W003/083098

(30) Priority Data

(31) Number	(32) Date	(33) Country
102 14 082.0	2002 .03 .28	DE
102 33 676.8	2002 .07 .24	DE
		20080306

(43) Publication Date : 2003 .10 .13

(43) Publication Journal Date : 2003 .11 .20

(71) Applicant(s)  
Biomay AG

(72) Inventor(s)  
Wally, Verena, Schneider, Peter, Breitenbach, Michael, Richter, Klaus, Simon-Nobbe, Birgit, Teige, Markus, Radauer, Christian, Ebner, Christof, Denk, Ursula

(74) Agent/Attorney  
Davies Collison Cave, 255 Elizabeth Street, Sydney, NSW, 2000

(56) Related Art  
Breitenbach et al (1997) Enolases and highly conserved fungal allergens International Archives of Allergy and Immunology 113(1-3): 114-117.  
Noeldner et al (1994) Purification and characterisation of mannitol dehydrogenase from the fungal tomato pathogen Cladosporium fulvum Molecular Plant Pathology 45(4): 281-289.  
Database SWISSPROT Accession No: Q96W29 Cladosporium fulvum, NADP-dependent mannitol dehydrogenase Pike et al  
Vouge et al (1998) Molecular cloning of IGE-binding fragments of Alternari alternata allergens International Archives of Allergy and Immunology 116(4):261-268.  
Hult et al (1980) The distribution of the NADPH regenerating mannitol cycle among fungal species Archives of Microbiology 128(2): 253-255.

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES  
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum  
Internationales Büro



(43) Internationales Veröffentlichungsdatum  
9. Oktober 2003 (09.10.2003)

PCT

(10) Internationale Veröffentlichungsnummer  
WO 2003/083098 A3

- (51) Internationale Patentklassifikation: C12N 9/04, C07K 14/37, A61K 39/35 (74) Anwälte: KELLER, Günter nsw.; LEIDNER & KELLER, Prinzregentenstrasse 16, 80538 München (DE).
- (21) Internationales Aktenzeichen: PCT/EP2003/002873 (81) Bestimmungsstaaten (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) Internationales Anmeldedatum: 19. März 2003 (19.03.2003) (84) Bestimmungsstaaten (regional): ARIPO-Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (25) Einreichungssprache: Deutsch
- (26) Veröffentlichungssprache: Deutsch
- (30) Angaben zur Priorität:  
102 14 082.0 28. März 2002 (28.03.2002) DE  
102 33 676.8 24. Juli 2002 (24.07.2002) DE
- (71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von US): BIOMAY PRODUKTIONS- UND HANDELS-AKTIENGESELLSCHAFT [AT/AT]; Bohr-Gasse 7b, A-1030 Wien (AT).
- (72) Erfinder; und
- (75) Erfinder/Anmelder (nur für US): SIMON-NOBBE, Birgit [AT/AT]; Ulrich-Schreierstr. 17, A-5020 Salzburg (AT). SCHNEIDER, Peter [AT/AT]; Höhenröth 4, A-4894 Oberhofen (AT). DENK, Ursula [AT/AT]; Forsthausstr. 42, A-4060 Leonding (AT). WALIY, Verena [AT/AT]; Schrammng. 12, A-5020 Salzburg (AT). RICHTER, Klaus [AT/AT]; Flurweg 1, A-5020 Salzburg (AT). RADAUER, Christian [AT/AT]; Wurmserg. 21, A-1150 Wien (AT). TEIGE, Markus [DE/AT]; Weyringerg. 7, A-1040 Wien (AT). EBNER, Christof [AT/AT]; Heinrich Albrecht-G. 19, A-2345 Brunn am Gebirge (AT). BREITENBACH, Michael [AT/AT]; Lederwaschg. 22, A-5020 Salzburg (AT).
- Veröffentlicht:  
— mit internationalem Recherchenbericht  
— vor Ablauf der für Änderungen der Ansprüche geltenden Frist; Veröffentlichung wird wiederholt, falls Änderungen eintreffen
- (88) Veröffentlichungsdatum des internationalen Recherchenberichts: 25. März 2004
- Zur Erklärung der Zweibuchstaben-Codes und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.

WO 2003/083098 A3

(54) Title: NUCLEIC ACID SEQUENCE AND PROTEIN IN ADDITION TO POLYPEPTIDES CODING FOR MANNITOL-DEHYDROGENASES OR PARTS THEREOF AND THE PRODUCTION AND USE THEREOF IN DIAGNOSIS AND THERAPY

(54) Bezeichnung: NUCLEINSÄURESEQUENZ UND PROTEIN SOWIE POLYPEPTIDE KODIEREND FÜR MANNIT-DEHYDROGENASEN ODER DEREN TEILE SOWIE DEREN HERSTELLUNG UND VERWENDUNG IN DIAGNOSTIK UND THERAPIE

(57) Abstract: The invention relates to polypeptides made of mannitol-dehydrogenase of Cladosporium herbarum and Alternaria alternata nucleic acids coding therefor and the use thereof in diagnosis and therapy.

(57) Zusammenfassung: Offenbart werden Polypeptide aus der Mannit-Dehydrogenase von Cladosporium herbarum und Alternaria alternata, hierfür kodierende Nukleinsäuren und deren Verwendung in Diagnostik und Therapie.

2003219084 18 Dec 2007

-1-

In certain people, allergic reactions are caused by a wide range of substances. Not only allergies to components of animals, such as, for example, cat hairs, but also allergies to plants and plant parts, such as the pollen of flowers, are known. However, allergies to microorganisms such as, for example, molds, are also known.

The present invention relates to the major allergen of the mold *Cladosporium herbarum*. It has been found within the scope of the present invention that, surprisingly, this major allergen is a mannitol dehydrogenase (MtDH). The present invention furthermore relates to a major allergen of *Alternaria alternata*.

Accordingly, a first aspect of the present invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:4, 5 or 6 or comprising at least 100 consecutive amino acids from the amino acid sequence of SEQ ID NO:1 or 8, wherein the polypeptide is an allergen.

In a second aspect, the present invention provides an isolated polypeptide comprising at least 100 consecutive amino acids from the amino acid sequence of SEQ ID NO:11 wherein the polypeptide is an allergen.

In a third aspect, the present invention provides a vaccine for desensitizing patients to a mould allergy, comprising at least one allergen as defined in the first or second aspect.

30

2003219084 18 Dec 2007

-1a-

In a fourth aspect, the present invention provides the use of an allergen as defined in the first or second aspect for the preparation of a vaccine.

- 5 In a fifth aspect, the present invention provides the use of an allergen as defined in the first or second aspect for the diagnostic detection of a disease.

- 10 In a sixth aspect, the present invention provides use of a polynucleotide for detecting a mannitol dehydrogenase, wherein the polynucleotide comprises at least eight consecutive nucleotides from the nucleotide sequence of SEQ ID NO:2, 7 or 12, wherein the nucleotide sequences of SEQ ID NOS:2, 7 and 12 encode mannitol dehydrogenases.

- 15 In a seventh aspect, the present invention provides a vector for transforming a host cell, wherein the vector comprises a polynucleotide comprising at least eight consecutive nucleotides from the nucleotide sequence of SEQ ID NO:2, 7 or 12, wherein the nucleotide sequences of SEQ ID NOS:2, 7 and 12 encode mannitol dehydrogenase.

- 20 In an eighth aspect, the present invention provides a host cell transformed with a vector as defined in the seventh aspect.

- 25 In a ninth aspect, the present invention provides a method for the preparation of an allergen as defined in the first or second aspect, wherein a host cell as defined in the eighth aspect is cultured, the polypeptide expressed and purified.

2003219084 18 Dec 2007

-1b-

The present invention relates to a polypeptide which has at least 10 consecutive amino acids from the amino acid sequence with the sequence ID No. 1. The amino acid sequence is shown in Fig 1, as is the corresponding DNA  
5 sequence. The invention also relates to the polypeptides with the seq ID No. 4, 5 and 6.

The complete sequence of a polypeptide encoding a mannitol dehydrogenase is furthermore disclosed. Seq. ID No. 7  
10 represents the nucleic acid sequence and seq. ID no. 8 the amino acid sequence thereof. The sequences are shown in Figure 3.

The present invention relates to a  
15

polypeptide which has at least 10 consecutive amino acids from the amino acid sequence with the sequence ID No. 11. The amino acid sequence is shown in Fig. 4; it constitutes a major allergen which has been isolated from *Alternaria alternata*.

The amino acid sequence of the major allergen from *Alternaria alternata*, which is mannitol dehydrogenase, is shown in Fig. 5 in the one-letter code, together with the DNA sequence encoding it (sequence ID No. 12) and the flanking nucleotide sequences at the 5' and the 3' end.

A polypeptide according to the invention preferably has at least one epitope. An epitope is understood as meaning a region to which antibodies can bind. In principle, there are linear epitopes. In this case, the amino acids which form the epitope are arranged next to one another. However, what are known as the confirmation epitopes are more frequent. These confirmation epitopes are formed by the folding of the polypeptide. Here, amino acids which are not adjacent in the sequence can come into spatial vicinity owing to the three-dimensional folding of the polypeptide, and this surface structure is bound by an antibody.

Preferably, the epitopes are specific for one mold. In principle, antibodies against virtually all amino acid sequences can be generated with the aid of suitable techniques, for example using adjuvants. The polypeptides according to the invention, however, play an important role in diagnostics and therapy. This is why the polypeptides according to the invention preferably have specific epitopes, the epitopes being specific for one mold. Frequently, proteins or polypeptides which originate from a certain organism have similarities to a corresponding protein or polypeptide which originates from a related organism. It is therefore possible that antibodies which are

directed against an epitope of a certain mold also react with a corresponding epitope of a related mold.

5 The more specific an epitope, the less antibodies which are directed against it will react with an epitope of a homologous polypeptide from a related organism. Thus, the polypeptides according to the invention preferably have those epitopes which are specific for a mold. The polypeptides especially preferably have those epitopes  
10 which are specific for a mold of the genus Cladosporium. The polypeptides very especially preferably have an epitope which is specific for Cladosporium herbarum. Antibodies which are directed against such an epitope do not react with other  
15 polypeptides.

It has been found within the scope of the present invention that the polypeptide with the amino acid sequence ID No. 1 encodes a mannitol dehydrogenase. The  
20 present invention also relates to parts of this amino acid sequence with at least 11 amino acids. The polypeptides according to the invention preferably have at least 20 consecutive amino acids from the sequence with the sequence ID No. 1. More preferred are those  
25 polypeptides which have at least 50 consecutive amino acids, and very especially preferred are those polypeptides which have at least 100 consecutive amino acids from the amino acid sequence with the sequence ID No. 1.

30 The invention also relates to a polypeptide from the N-terminus with the sequence PGQQATKHESLLDQLS (seq. ID No. 4) and to two polypeptides from the C-terminal end with the sequence LDTGLSDFVVK (seq. ID No. 5) and  
35 MGRDGLAKEL (seq. ID No. 6).

The invention also relates to a polypeptide with the sequence ID No. 8 and to parts of this polypeptide which comprise an epitope. The parts according to the

invention of the sequence ID No. 8 have at least 11, preferably at least 20, more preferably at least 50 and very especially preferably at least 100 consecutive amino acids from the amino acid sequence with the  
5 sequence ID No. 8.

The present invention furthermore relates to a polypeptide with the sequence ID No. 11 and to parts of this polypeptide which comprise an epitope. Such  
10 epitopes are specific for *Alternaria*, more precisely for *Alternaria alternata*. The parts according to the invention of the sequence ID No. 11 have at least 11, preferably at least 20, more preferably at least 50 and especially preferably at least 100 consecutive amino  
15 acids from the amino acid sequence with the sequence ID No. 11.

These polypeptides preferably have at least one epitope. For example, it is possible, with the aid of  
20 hydrophilicity/hydrophobicity examinations, to identify those parts of the polypeptide which are especially suitable for immunological reactions. This can be done for example with the aid of suitable computer programs.

25 As an alternative, it is also possible to prepare fragments of the sequence with the aid of what is known as the Pepscan method and to test the short fragments for relevant epitopes by reacting them with sera from allergic patients. Moreover, it must be identified  
30 whether the epitopes are epitopes which are specific for a mold, in particular for a mold from the genus *Cladosporium* and/or *Alternaria* and in particular for *Cladosporium herbarum* and/or *Alternaria alternata*. This determination is carried out using suitable serum  
35 panels.

*Cladosporium* is a fungal genus which belongs to the molds. *Cladosporium* species are very frequent and occur preferentially in bogs, in forests and in gardens since



they grow readily on rotten plants or on leaves. Moreover, they are found in greenhouses and in insufficiently cleaned refrigerators. Cladosporium also grows on textiles, for example linen fabrics.

- 5 Cladosporium can trigger allergic reactions such as, for example, running nose, cough, sneezing, urticaria or asthma (mold allergy).

- 10 Alternaria is a fungal genus which belongs to the molds. Alternaria species occur preferentially in bogs, in forests and in gardens since they grow readily on rotten plants or on leaves. On domestic premises, they are mainly found in flour, fruit and vegetables. However, they also grow on a variety of textiles, for  
15 example linen fabrics. Alternaria can trigger allergic reactions such as, for example, running nose, cough, sneezing, urticaria or asthma (mold allergy).

- Owing to the disclosure of the amino and nucleic acid  
20 sequence, it is possible, with the aid of recombinant techniques, to prepare shorter fragments of the complete sequence recombinantly in bacteria, for example in E. coli, or in higher organisms, for example insect cells, yeasts or eukaryotic cells. It is  
25 precisely short polypeptides that can also be provided readily via the chemical route with the aid of solid-phase synthesis.

- The present invention furthermore relates to a vaccine  
30 which can be employed for desensitizing patients to a mold allergy. In the desensitization, patients who suffer from an allergy are brought into contact with a small amount of an antigen, whereby it is intended that neutralizing IgE antibodies are formed. The antigens  
35 with which the patient has come into contact are bound by these neutralizing antibodies. The antigen-antibody binding of antibodies of the IgE type, which trigger allergic reactions, are thereby avoided. The polypeptides according to the invention can therefore

be used for preparing a vaccine. To this end, the recombinantly produced, or else chemically produced, polypeptides can be incorporated into a suitable vaccine formulation. In addition to the polypeptides, 5 the vaccine formulation can also comprise conventional additives and formulation auxiliaries, as well as adjuvants.

10 The present invention also relates to the use of a polypeptide according to the invention for a diagnostic detection of a disease. Such a disease usually takes the form of an allergy. The polypeptides are employed in a suitable diagnostic detection system. This may take the form of a radioimmunoassay (RIA), or 15 preferably also an ELISA (enzyme-linked immunosorbent assay). The usual configuration of such a diagnostic assay is known.

20 Another aspect of the present invention relates to nucleotides from the nucleotide sequence with the sequence ID No. 2. The nucleotide sequence with the sequence ID No. 2 is likewise shown in Figure 1. It is part of the gene for the *Cladosporium herbarum* mannitol dehydrogenase according to the invention.

25 A further aspect of the present invention relates to polynucleotides with the nucleotide sequence of the sequence ID No. 7. Parts of this nucleotide sequence are likewise the subject-matter of the invention. With 30 the aid of this nucleotide sequence or parts thereof, a desired polypeptide can be produced recombinantly in suitable host cells.

35 A further aspect of the present invention relates to polynucleotides with the nucleotide sequence, sequence ID No. 12. This is a nucleotide sequence which encodes the *Alternaria alternata* mannitol dehydrogenase and nucleotide sequences which are immediately adjacent to the coding region. Parts of this nucleotide sequence

are also the subject-matter of the present invention.

A polynucleotide according to the invention has at least eight consecutive nucleotides, preferably at least 12, more preferably at least 20 and most preferably at least 50 consecutive nucleotides. For some fields of application, the nucleotides must be longer, in which case the polynucleotides have at least 100 consecutive nucleotides selected from the sequence ID No. 2, ID No. 7 or sequence ID No. 12.

The polynucleotides according to the invention can be used for detecting a mannitol dehydrogenase. It is preferred to detect the presence of a gene encoding this mannitol dehydrogenase from *Cladosporium herbarum* and/or *Alternaria alternata*. These methods take the form of nucleic acid amplification methods which are known per se. A suitable example for this purpose is NASBA (nucleic acid sequence based amplification) or, more preferably, polymerase chain reaction (PCR).

Since the nucleic acid sequences encoding the *Cladosporium herbarum* and *Alternaria alternata* mannitol dehydrogenase have been disclosed, it is possible to select those nucleotide sequences for the amplification which have a very high degree of homology, or even identity. It can be expected that, when using such highly-specific primers, other mannitol dehydrogenases from related organisms are also amplified since a high degree of homology in the amino acid sequences suggests a high degree of conservation in such a gene region.

Thus, it is preferred to use such highly conserved regions for nucleic acid diagnostics in the case when the antigen is to be isolated not only from *Cladosporium* and/or *Alternaria* species, but also from other mold species.

Regions which have a low degree of homology with one

another are therefore better suited for fine diagnostics, that is to say for the distinction both between *Alternaria* and *Cladosporium* species and for the fine differentiation within *Cladosporium* or *Alternaria* species. Figure 6 shows the coding regions from *Cladosporium herbarum* and *Alternaria alternata* together. Identical nucleotide sequences are shown against a black background and identify conserved regions.

Such a method can be used for detecting the presence of the mold *Cladosporium herbarum* and/or *Alternaria alternata*. Such applications are of interest not only in medical diagnostics, but also in other fields, for example in the fields of hygiene and food testing. In this context, it must be taken into consideration that *Cladosporium herbarum* is capable of growth even at relatively low temperatures of up to approximately +6°C and that it can therefore constitute an undesired contamination in fields of food technology. The detection even of small amounts of *Cladosporium herbarum* may play an essential role in the control of foods and their quality control.

A further aspect of the present invention is the disclosure of a method for preparing a polypeptide according to the invention. First, a gene from a mold, preferably from *Cladosporium herbarum* or *Alternaria alternata*, can be amplified with the aid of the polynucleotides according to the invention and with the aid of the polymerase chain reaction. This polynucleotide can then be incorporated into a suitable vector with which a host cell is transformed. Suitable vectors multiply in the host cell, during which process the polypeptides are expressed. The host cells may take the form of conventional host cells. Suitable for this purpose are bacterial host cells such as *Escherichia coli* or *Bacillus subtilis* or yeasts such as, for example, *Saccharomyces cerevisiae* or *Pichia pastoris*.

For the purposes of the present invention, IgE immunoblots of *Cladosporium herbarum* crude extract were assayed with sera from 62 patients. An immunoreactive protein of molecular weight 29 kD, which was recognized by 61% of the patients' sera, was identified. The patients had been preselected in a skin test or blood test (RAST) and showed a positive response to *Cladosporium herbarum* extract. No other allergen in the *Cladosporium herbarum* extract reacted with such a high percentage of patients' sera. It is therefore assumed that this protein is the major allergen of *Cladosporium herbarum*.

The immunoreactive proteins disclosed within the scope of the present invention are important allergens, not only for diagnostic purposes, but also for the therapy of allergens to molds, in particular *Cladosporium* and *Alternaria* species. If appropriate, these allergens, together with other allergens, for example Alt a 1 [Unger A. et al. (1999), Clinical testing of recombinant allergens of the mold *Alternaria alternata*, Int. Arch. Allergy Immunol. 118, 220-221] and Enolase [Simon-Nobbe B. et al. (2000), IgE binding epitopes of enolases, a class of highly conserved fungal allergens, I. Allergy Clin. Immunol. 106, 887-895] can be employed both in diagnostics and for therapeutic purposes.

The two-dimensional separation by isoelectric focusing and SDS-PAGE showed this *Cladosporium herbarum* protein as a 29 kD spot and at isoelectric point at pH = 5.8.

The protein was purified to homogeneity in a conventional method (example 1). The yield amounted to 1 mg. The homogeneously purified protein was then assayed in the IgE immunoblot with a pool of six patients and was highly positive (example 2).

The protein which had been purified to homogeneity was

partially sequenced by Edmanic degradation, starting at the N terminus, and internal peptide sequences were determined after degradation with CNBr.

- 5 N-terminal and internal peptide sequences were determined after digestion with trypsin by subjecting approximately 50 µg of protein, which had been obtained by excising a spot from the two-dimensional electrophoresis, to Edman degradation.
- 10 Table 1 shows a list of all peptide sequences which were identified. The single-letter code was used. The amino acids which are shown against the black background in table 1 were found in the sequence of the
- 15 *Cladosporium fulvum* mannitol dehydrogenase.

Peptide sequences of the C. herbarum NADP-dependent  
mannitol dehydrogenase, N-terminal sequence

PGQ<sup>Q</sup>QATKHES<sup>LDQ</sup>SLK<sup>SK</sup>: a) Starting material: crude  
extract separated by  
means of 2-dimensional  
SDS gel

b) Analytical method: Edman  
sequencing

PGQ<sup>Q</sup>QATKHES<sup>LDQ</sup>SLK<sup>SK</sup>: a) Starting material: native  
purified protein

b) Analytical method: Edman  
sequencing

Peptide 1

5

HES<sup>LDQ</sup>SLK<sup>SK</sup>: a) Starting material: crude extract  
separated by means of 2-  
dimensional SDS gel

b) Analytical method: MS/MS

c) Note: overlaps with the N-terminal  
sequence

Peptide 2

W<sup>W</sup>VTGASGF: a) Starting material: crude extract  
separated by means of 2-  
dimensional SDS gel

b) Tryptic digest

c) Analytical method: sequencing

W<sup>W</sup>VTGASKR: a) Starting material: crude extract  
separated by means of 2-  
dimensional SDS gel

b) Tryptic digest

c) Analytical method: MS/MS

Peptide 3

QVDSYE: a) Starting material: crude extract  
separated by means of 2-  
dimensional SDS gel

b) Tryptic digest

c) Analytical method: sequencing

**Peptide 4**

**LDTGLSDFVVK**

- a) Starting material: crude extract separated by means of 2-dimensional SDS gel
- b) Tryptic digest
- c) Analytical method: MS/MS

**Peptide 5**

**MGRDGLAKEL**

- a) Starting material: native purified protein
- b) CnBr digest
- c) Analytical method: sequencing

Table 1

The peptide sequences were compared with all the protein sequences listed in the databases (Swissprot, GenBank and the like) by computer-aided homology search. All peptides showed homology with the family of the mannitol dehydrogenases. The mannitol dehydrogenase with which the peptides show the highest degree of sequence similarity is the *Cladosporium fulvum* mannitol dehydrogenase. A purification of *Cladosporium fulvum* mannitol dehydrogenase is described in Noeldner et al., Physiological and Molecular Plant Pathology (1994) pp. 281-289. The position of these peptides in the sequence can be seen in the alignment (Table 2).



Protein alignment of the C. fulvum NADP MtDH and C. herbarum peptide sequences

```

C.fulvum      1 MFRIPRAHDELLMRRVVTSSRQKMGIEAARGCAEMCADLAIITYASRAEGGL
C.herbarum    PCQATKHESLEKCSLECKKAAVTGARE-----
C.fulvum      61 KNAEELSKQYGIKCKAYKCSVEQLVKDVIQDFGKIDAFIANAGATANSGLDGS
C.herbarum    -----CHLSF-----
C.fulvum     121 VEDWNHVVVQVDLNGTFHCAKAVGHFHKERTGTSFVITSSMSGHIANYPQEQTSYNVAKAG
C.herbarum    -----
C.fulvum     181 CIHMARSLANEMWDFARVNSISPGYITGSGDPPHARDIQKLWHSMIPLGRDGLAKETKGA
C.herbarum    -----LDTGLSDPPHVR-----MDDSLAKEL-----
C.fulvum     241 YVYLVSASTYTTGADIVIDGGYTCT
C.herbarum    -----

```

5

C.fulvum MtDH: accession number: AAK67169 (seq. ID No. 3)

Length of the coding sequence: 267 amino acids (AA)  
801 base pairs (bp)

10 MW: 28.6 kD  
pI: 6.33

Table 2

15 Table 2 shows the arrangement of the polypeptides with seq. ID No. 4, 5 and 6 with reference to the homology with C. fulvum.

Owing to these results, the enzyme activity of the protein which had been purified to homogeneity was assayed. The experiments reveal that the highly purified major allergen of Cladosporium herbarum is indeed a mannitol dehydrogenase which catalyzes the following metabolic reaction: Fructose + NADPH + H<sup>+</sup> ⇌ mannitol + NADP<sup>+</sup>. Furthermore, it has been found that NADH is not active as cosubstrate and that fructose-6-phosphate is also not active as substrate. Fructose-6-phosphate has an inhibitory effect on the reaction. The method of the activity determination is described in example 3.

20  
25  
30

Then, the N-terminal peptide sequence and an internal peptide sequence of the *Cladosporium herbarum* mannitol dehydrogenase were used for designing PCR primers by means of back translation. The primer selection is compiled in table 3.

**DNA sequence of the oligos derived from the peptides**

**Oligo 1:**

- derived from the N-terminal sequence of the *C. herbarum* mannitol dehydrogenase (MtDH) (see seq. ID No. 2)
- oligo sequence: 5' CA(A/G) CA(A/G) GC(I/C) AC(I/C) AA(A/G) CA(C/T) GA 3'

**Oligo 2:**

- derived from peptide 4 of the *C. herbarum* MtDH
- oligo sequence: 5' AC(A/G) AA(A/G) TC(A/G) CT(I/C) AG(I/C) CC(A/G) GT(A/G) TC 3'

The primers are mixtures of synthetic oligonucleotides. (A/G)... means that both adenine and guanine are found in the oligonucleotides at this position. The same applies to (C/T) and (I/C), where I represents the base inosine.

**Table 3**

These primers which are shown in table 3 were used to carry out a PCR reaction with the DNA from a *Cladosporium herbarum* cDNA library constructed by the inventors (Achatz G et al., 1995, Mol. Immunol., 32; 213-27). The result was a 636 bp band. This band was sequenced by automated DNA sequencing as described by Sanger (1977, Proc. Natl. Acad. Sci. USA, 74; 5463-7) using the PCR primers as sequencing primers. Seq. ID No. 2 was identified in this process. The protein sequence (seq. ID No. 1) derived from this DNA sequence has 87% identity with the protein sequence of the

Cladosporium fulvum mannitol dehydrogenase. If the substitution by chemically related amino acids (for example I - V, isoleucine - valine and the like) is also taken into consideration, this value rises to 92%.

- 5 With the plausible assumption that the Cladosporium herbarum mannitol dehydrogenase, like the Cladosporium fulvum mannitol dehydrogenase, has a total length of 267 amino acid, as much as 65% of the amino acid sequence of the major allergen (mannitol dehydrogenase)
- 10 from Cladosporium herbarum were determined by firstly peptide sequencing and secondly DNA sequencing. The total sequence of this protein which is known to date, and the alignment of this sequence with the homologous Cladosporium fulvum sequence, are shown in figure 2.

15

#### **Example 1**

##### Protein purification

- 20 1. Ammonium sulfate precipitation:

Prefractioning can be achieved by an ammonium sulfate concentration of 50%, with mannitol dehydrogenase (MtDH) remaining in the supernatant.

25

50 mM Tris-HCl, pH 7.5 were added to the extract. Proteases were inhibited with 1 tablet of Roche Complete per 100 ml of extract and 2 mM EDTA.

- 30 The precipitation was carried out by adding solid, ground ammonium sulfate and was carried out in two steps, first 0-30%, then 30-50%. The precipitation was equilibrated for at least 45 minutes before the extract was centrifuged at 12 000 g. The supernatant was
- 35 filtered and purified further via hydrophobic interaction chromatography (HIC).

2. HIC (Phenyl-Sepharose):

The supernatant from the ammonium sulfate precipitation was brought to pH 6.5 using 3 M sodium acetate. The column (8 ml Source, 15 PHE, PHARMACIA) was equilibrated with 1.2 M ammonium sulfate, 50 mM Tris-HCl, pH 7.5, 2 mM EDTA and loaded with the sample at a flow rate of 1 ml/min. After the column had been washed with 20 ml of buffer, it was eluted with a gradient of 1.2 M ammonium sulfate to 0.6 M ammonium sulfate over 40 ml.

The mannitol dehydrogenase (MtDH) fractions were pooled and prepared for the anion exchanger. The volume is concentrated via Centricon centrifuge tubes (Millipore); buffer exchange flow 50 mM Tris-HCl, pH 7.5 with the aid of PD-10 Desalting Columns (AMERSHAM-PHARMACIA).

### 3. Anionic exchanger (Q-Sepharose):

The column (8 ml Source 15 Q, PHARMACIA) was equilibrated with 15 mM Tris-HCl, pH 7.5. It was eluted with a 0-300 mM NaCl gradient over 100 ml.

### Example 2

Immune blot of the native purified MtDH after separation in the SDS gel

Native purified MtDH was separated by molecular weight in a reducing SDS gel (Laemmli UK, Nature, 1970; 27:680-5). Subsequently, the protein was transferred onto a PVDF membrane in a Western blot (Towbin H et al., Proc. Natl. Acad. Sci USA, 1979; 76:4350-4). After free binding sites had been saturated (30 minutes in blocking buffer: 50 mM sodium phosphate pH 7.5, 0.5% Tween 20, 0.5% BSA, 0.05%  $\text{NaN}_3$ ), the membrane was incubated with patients' serum (1:10 diluted in blocking buffer). Then, the membrane was washed (with blocking buffer, 3 x 10 minutes) to remove

unspecifically bound antibodies. Specifically bound IgE-Ab were detected with the aid of an <sup>125</sup>I-labeled rabbit anti-human IgE antibody. After the membrane had been exposed to an X-ray film, the result was available.

Results:

- 1) The native purified MtDH reacts specifically with the IgE antibodies of C. herbarum allergy sufferers. A prominent IgE-reactive band is revealed at 29 kD.
- 2) The same result, viz. a prominent IgE-reactive band at 29 kD, is obtained when a C. herbarum total extract is separated in the SDS gel and subsequently incubated with patients' serum in an immune blot.

**Example 3**

Immune blot of the native purified MtDH after 2-dimensional separation

Native purified MtDH was separated under denaturing conditions in an isoelectric focusing (O'Farrel PH, J. Biol. Chem., 1975; 250:4007-21) according to the net charge (isoelectric point) of the protein. Thereafter, the protein separated thus was subjected to SDS gel electrophoresis (Laemmli UK, Nature, 1970; 27:680-5), whereby a separation by molecular weight took place in addition. The protein was transferred to a PVDF membrane in a Western blot (Towbin H et al., Proc. Natl. Acad. Sci. USA, 1979; 76:4350-4). After free binding sites had been saturated (30 minutes in blocking buffer: 50 mM sodium phosphate pH 7.5, 0.5% Tween 20, 0.5% BSA, 0.05% NaN<sub>3</sub>), the membrane was incubated with patients' serum (1:10 diluted in blocking buffer). Then, the membrane was washed (with blocking buffer, 3 × 10 minutes) to remove unspecifically bound antibodies. Specifically bound

IgE-Ab were detected with the aid of an  $^{125}\text{I}$ -labeled rabbit anti-human IgE antibody. After the membrane had been exposed to an X-ray film, the results were available:

5

Results:

1) The native purified MtDH reacts specifically with the IgE antibodies of C. herbarum allergy sufferers. A prominent IgE-reactive spot was observed at a molecular weight of 29 kD and an isoelectric point of 5.8.

2) The same result, viz. a prominent IgE-reactive spot at a molecular weight of 29 kD and an isoelectric point of 5.8 is obtained when a C. herbarum total extract is separated in a two-dimensional gel and subsequently incubated with patients' serum in an immune blot. An IgE-reactive protein with a molecular weight of 29 kD and an isoelectric point of 5.6 is additionally found in the total extract. This protein could be an MtDH isoform.

**Example 4**

To confirm the results according to the invention, the enzyme activity was determined with the traditionally purified protein. The absorption of NADPH was measured in a photometer at 340 nm.

Reaction mix (1 ml):

50 mM Tris-HCl, pH 7.5

0.25 mM NADPH or NADH

D-fructose or fructose-6-phosphate (0.1; 0.2; 0.4; 0.6;

0.8; 1.0; 1.2 M)

H<sub>2</sub>O to 1 ml

the reaction is started with 0.5  $\mu\text{l}$  of MtDH

Results:

Reaction with fructose and NADPH  
No reaction with fructose-6-phosphate and NADH

# 5 Example 5

## Sequence of mannitol dehydrogenase (MtDH)

The complete sequence of the *Cladosporium herbarum* mannitol dehydrogenase was determined as described hereinbelow.

The peptide sequences obtained by Edman degradation of the *Cladosporium* mannitol dehydrogenase which had been purified to homogeneity were used to synthesize primer mixtures for the PCR. The PCR resulted in a band of 636 nt which was firstly sequenced and secondly used as hybridization probe for screening our cDNA library. A complete *Cladosporium herbarum* mannitol dehydrogenase (MtDH) clone was isolated and sequenced. The complete sequence is shown in fig. 3; it has 84% identity with the published sequence of the *C. fulvum* MtDH.

Table 4 shows the sequence alignment of the two mannitol dehydrogenases of *Cladosporium herbarum* and *Cladosporium fulvum*, only the amino acids which differ being shown.

Table 4: Alignment of the amino acid sequences of the *C. herbarum* and *C. fulvum* MtDHs:

<i>C. fulvum</i>	1	-MPGRIPKRAHLL	121	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC
<i>C. herbarum</i>	1	MPGQDAIKHSHL	121	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC
<i>C. fulvum</i>	60	LKQAEISQVNL	180	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC
<i>C. herbarum</i>	61	EEVVKHEDTFLA	181	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC
<i>C. fulvum</i>	120	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC	240	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC
<i>C. herbarum</i>	121	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC	241	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC
<i>C. fulvum</i>	180	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC		
<i>C. herbarum</i>	181	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC		
<i>C. fulvum</i>	240	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC		
<i>C. herbarum</i>	241	STLYSRQVYDAGDFRQNTIAAPQVNERGDAITVASDEEC		

Amino acid sequences which are shown against the black background mean identical amino acid sequences, chemically similar amino acids are shown against a grey background, and amino acids which differ are shown against the normal background.

The *C. fulvum* sequence is represented as seq. ID No: 9, and the *C. herbarum* amino acid sequence as SEQ. ID No: 10.

- Table 4 shows the regions of the polypeptide which may be suitable for the detection of or a vaccine for *Cladosporium*. They are the regions with no differences.
- In the regions with pronounced differences it must be presumed that the immunological reactions differ; such regions can therefore comprise highly specific epitopes.
- When determining the sequence shown in fig. 3, it was found that minor differences occurred in the nucleotide sequence in comparison with the originally isolated part-sequences. This can be attributed to differing sequences which were present in the gene library.
- However, these differences do not affect the present invention in any way. The invention relates to the disclosed differing sequences, since it is assumed that they are variants of the gene.

#### Example 6

##### Expression in *E. coli*, and reactivity with patients' serum

- The open reading frame of MtDH was cloned into the following expression vectors:
- a) pHis-Parallel 2 Vector (XhoI/BamHI) (Ref.: P. Sheffield, S. Garrard, and Z. Derewenda (1999). Overcoming expression and purification problems of



RhoGDI using a family of "parallel" expression vectors. Protein Expr Purif 15,34.)

- b) pMW172 Vector (NdeI/EcoRI) (Ref.: M. Susani, P. Jertschin, C. Dolecek, W. R. Sperr, P. Valent, C. Ebner, D. Kraft, R. Valenta, and O. Scheiner (1995). High level expression of birch pollen profiling (Bet v 2) in *Escherichia coli*: purification and characterization of the recombinant allergen. Biochem Biophys Res Commun 215, 250.)

The plasmids were subsequently transformed into *Escherichia coli* strain BL21 (DE3). For the subsequent induction, 5-ml-portions of LBamp were inoculated with 50 µl of a stationary overnight culture of the two clones and the mixtures were shaken at 37°C until a OD<sub>600</sub> of 0.8 had been reached (approx. 4 hours). The protein expression was induced with 0.8 mM IPTG. After incubation for 4 hours at 37°C in a shaker-incubator, the *E. coli* suspensions were spun down for 15 minutes at 4000 rpm. The bacterial pellets were subsequently resuspended in 1 ml of 1xPBS, and 6-µl-portions of the dissolved bacterial pellets were separated by SDS-PAGE and subsequently stained with Coomassie BBR250. This gave the following results: the *E. coli* cells which had been transformed with the expression plasmids and induced with IPTG, but not the *E. coli* cells without plasmid, reveal a pronounced protein band at the molecular weight expected in each case, viz. 30 kD and approximately 33 kD, respectively (apparent molecular weight).

An IgE immune blot was carried out with the polypeptides which had been separated with the aid of a gel. The serum of a *Cladosporium*-positive allergy sufferer was used. The bound IgE antibodies were detected with the <sup>125</sup>I labeled rabbit anti-human IgE antibody (RAST). The two foreign proteins which were overexpressed in *E. coli* react strongly with the IgE of

the patient, but not the proteins of *E. coli* itself.

**Example 7**

- 5 Determination of the frequency of the response to  
recombinant MtDH with the aid of 30 sera of  
Cladosporium-positive allergy sufferers

The experiment described in example 6 was repeated, but  
10 30 different Cladosporium-positive allergy-sufferer  
sera which had not been preselected were used. The  
control revealed a very low immune reactivity of the *E.*  
*coli* extract with the second antibody (RAST). This can  
probably be attributed to an artifact. As expected,  
15 other controls were negative.

Among 30 patients, 20 revealed an IgE-positive band at  
30 kD which was more pronounced than the weak band in  
the control experiment. MtDH is thus recognized by  
20 approximately two thirds of the Cladosporium-positive  
allergy sufferers. This finding is important because  
this experiment demonstrates that recombinant  
Cladosporium herbarum MtDH can be employed as  
diagnostic and therapeutic for the majority of the  
25 patients.

**Example 8**

To clone the *Alternaria alternata* mannitol  
30 dehydrogenase, a cDNA bank in Lambda-ZAP (Stratagene,  
La Jolla, CA, USA). This cDNA cloned library was  
prepared with the aid of isolated mRNA from *Alternaria*  
*alternata*.

35 As described above, the cDNA library was screened with  
a DNA probe, with initially 24 primary clones being  
isolated. 5 of these clones were sequenced completely.  
All 5 sequences were identical in the coding region.  
The translation of the nucleotide sequence into an

amino acid sequence and the comparison with the amino acid sequence of the *Cladosporium herbarum* mannitol dehydrogenase revealed that the reading frame was complete. The sequence had 74% identity with the sequence from *Cladosporium herbarum*.

#### Example 9

The open reading frame of the clone encoding the *Alternaria alternata* mannitol dehydrogenase was then recloned in the expression vector pHIS-parallel 2 [P. Sheffield et al. (1999), Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors, Protein Exp. Purif. 15, 34] using the restriction cleavage sites Bam H I (N-terminally) and Xho I (C-terminally). Upon expression in *E. coli* BL21 and subsequent analysis of the gene products with the aid of SDS-PAGE gel electrophoresis and Coomassie Blue staining, a pronounced protein band appeared at a molecular weight of approximately 30 kD. This corresponds approximately to the molecular weight which would be expected theoretically.

#### Example 10

The following procedure was chosen for purifying the recombinantly produced protein, which is provided with a poly-His fragment at the C terminus: the *E. coli* cells with the expression vector, which express the foreign protein, the *Alternaria alternata* mannitol dehydrogenase, were first lysed in the customary manner. It was found that the recombinantly produced protein was present in insoluble form. The inclusion bodies formed by overexpression of the foreign protein were first solubilized in a buffer with 6-molar urea and subsequently purified by affinity chromatography over a nickel chelate column. The recombinantly produced mannitol dehydrogenase was applied in 6 M urea buffer. Imidazole buffer was

2003219084 19 Sep 2007

- 24 -

employed for the elution. The protein-comprising fractions were subsequently purified further by preparative SDS-PAGE gel electrophoresis and analyzed, during which process it emerged that the allergen was already purified to virtually  
5 complete homogeneity. Staining with Coomassie-BB-R only revealed on band with a molecular weight of approximately 30 kD.

**Example 11**

10

The protein prepared in accordance with example 10 was separated by gel electrophoresis and tested in an IgE immune blot with the sera of 28 patients. All of the 28 sera originated from patients who had shown a positive response  
15 to the Alternaria alternate crude extract and who had been pretested both in a skin test and in an RAST. A pronounced band was visible in the immune blot in the case of 9 of the patients' sera tested. This corresponds to approximately 32% of the Alternaria alternate-sensitized patients.

20

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or  
25 step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

2003219084 19 Sep 2007

- 24a -

The reference in this specification to any prior publication  
(or information derived from it), or to any matter which is  
known, is not, and should not be taken as an acknowledgment  
or admission or any form of suggestion that that prior  
5 publication (or information derived from it) or known matter  
forms part of the common general knowledge in the field of  
endeavour to which this specification relates.

2003219084 18 Dec 2007

- 25 -

The claims defining the invention are as follows:

1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:4, 5 or 6 or comprising at least 100 consecutive amino acids from the amino acid sequence of SEQ ID NO:1 or 8, wherein the polypeptide is an allergen.
2. Allergen as claimed in claim 1, comprising at least one epitope.
3. Allergen as claimed in claim 2, wherein the epitope is specific for a mould belonging to the genus *Cladosporium*.
4. Allergen as claimed in claim 3, wherein the mould is *Cladosporium herbarum*.
5. Allergen as claimed in any one of claims 1 to 4, wherein the amino acid sequence of SEQ ID NO: 1 or 8 encodes a mannitol dehydrogenase.
6. An isolated polypeptide comprising at least 100 consecutive amino acids from the amino acid sequence of SEQ ID NO:11 wherein the polypeptide is an allergen.
7. Allergen as claimed in claim 6, comprising at least one epitope.
8. Allergen as claimed in claim 6, wherein the epitope is specific for a mould belonging to the genus *Alternaria*.

2003219084 18 Dec 2007

- 26 -

9. Allergen as claimed in claim 8, wherein the mould is *Alternaria alternata*.
10. Allergen as claimed in any one of claims 6 to 9, wherein the amino acid sequence of SEQ ID NO:11 encodes a mannitol dehydrogenase.
11. A vaccine for desensitizing patients to a mould allergy, comprising at least one allergen as claimed in any one of claims 1 to 10.
12. The use of an allergen as claimed in any one of claims 1 to 10 for the preparation of a vaccine.
13. The use of an allergen as claimed in any one of claims 1 to 10 for the diagnostic detection of a disease.
14. The use as claimed in claim 12 or 13, wherein the disease is an allergy against moulds.
15. Use of a polynucleotide for detecting a mannitol dehydrogenase, wherein the polynucleotide comprises at least eight consecutive nucleotides from the nucleotide sequence of SEQ ID NO:2, 7 or 12, wherein the nucleotide sequences of SEQ ID NOS:2, 7 and 12 encode mannitol dehydrogenases.
16. The use as claimed in claim 15, wherein at least one polynucleotide is used in a Polymerase Chain Reaction (PCR).

2003219084 18 Dec 2007

- 27 -

17. A vector for transforming a host cell, wherein the vector comprises a polynucleotide comprising at least eight consecutive nucleotides from the nucleotide sequence of SEQ ID NO:2, 7 or 12, wherein the nucleotide sequences of SEQ ID NOS:2, 7 and 12 encode mannitol dehydrogenase.
18. A host cell transformed with a vector as claimed in claim 17.
19. The host cell as claimed in claim 18, wherein the cell is *Escherichia coli*.
20. The host cell as claimed in claim 18, wherein the cell is *Pichia pastoris*.
21. A method for the preparation of an allergen as claimed in any one of claims 1 to 10, wherein a host cell as claimed in any one of claims 18 to 20 is cultured, the polypeptide expressed and purified.
22. An allergen as claimed in any one of claims 1 to 10, or a polynucleotide encoding the same, substantially as herein described with reference to the Examples.
23. Use of an allergen as claimed in any one of claims 1 to 10, or a polynucleotide encoding the same, substantially as herein described with reference to the Examples.



```

CTG AAG GGC AAG GTC GTC GTC GTT ACC GGC GCT TCC GGC CCC
L K G K V V V V T G A S G P
AAG GGC ATG GGT ATT GAG GCC GCT CGC GGT TGC GCC GAG ATG
K G M G I E A A R G C A E M
GGC GCC GCT GTT GCC ATC ACC TAC GCC TCC CGC GCC CAG GGT
G A A V A I T Y A S R A Q G
GCT GAG GAG AAC GTC AAG GAG CTT GAG AAG ACC TAC GGC ATC
A E E N V K E L E K T Y G I
AAG GCC AAG GCC TAC AAG TGC CAG GTC GAC AGC TAC GAG TCC
K A K A Y K C Q V D S Y E S
TGC GAG AAG CTC GTC AAG GAC GTC GTT GCC GAC TTC GGC CAG
C E K L V K D V V A D F G Q
ATC GAT GCC TTC ATC GCC AAC GCC GGT GCC ACC GCC GAC TCT
I D A F I A N A G A T A D S
GGC ATC CTC GAC GGC TCC GTC GAG GCC TGG AAC CAC GTC GTC
G I L D G S V E A W N H V V
CAG GTC GAC CTG AAC GGT ACC TTC CAC TGC GCC AAG GCC GTT
Q V D L N G T F H C A K A V
GGC CAC CAC TTC AAG GAG CGT GGA ACC GGT TCC TTC GTC ATC
G H H F K E R G T G S F V I
ACC TCC TCC ATG TCC GGC CAC ATC GCC AAC TAT CCC CAG GAA
T S S M S G H I A N Y F Q E
CAG ACC TCC TAC AAC GTC GCC AAG GCT GGA TGC ATC CAC ATG
Q T S Y N V A K A G C I H H
GCT CGC TCC TTG GCA
A R S L A

```

5 Figure 1

Figure 2

5 Alignment of the C. fulvum and C. herbarum NADP-MtDHs  
on the basis of the available DNA and protein data

```

C.fulvum      1 MFRRIPEPRLDLSLKGWVVVTGASGPKMGIEAARGCAEMGDAITYASPAEGSL
C.herbarum    PGQATKHRLDLSLKGWVVVTGASGPKMGIEAARGCAEMGDAITYASRAQGE

C.fulvum      61 MFAEELSLTGLNKKAYKCOVDYESLMLVKDVAQDFGLDAFIANAGATAHSGILDGS
C.herbarum    EIVKELSLTGLNKKAYKCOVDYESLMLVKDVAQDFGLDAFIANAGATAHSGILDGS

C.fulvum      121 VEGNNHVVQVDLNGTFHCAYGHHFKERGTGSEVITSSMSCHIANYPEQOTSNNVAKAG
C.herbarum    VEGNNHVVQVDLNGTFHCAYGHHFKERGTGSEVITSSMSCHIANYPEQOTSNNVAKAG

C.fulvum      181 EIHMAESLAHEWRDFARVVISISPGYDTGLSDFVADIQNLNHSNIPGRDGLAKELKGA
C.herbarum    EIHMAESLA-----DTGLSDFV-----GRDGLAKEL---

C.fulvum      241 YVVLVSASTYITGADIVIPGGYTCA
C.herbarum    -----

```

10

Alignment of the derived amino acid sequences of the  
 Cladosporium herbarum and Cladosporium fulvum mannitol  
 dehydrogenases.

- ... means that the amino acid sequence of C. herbarum

15 still requires sequencing at this position.

Fig. 3: Complete nucleotide and protein sequence of the  
Cladosporium herbarum MtDH

5

```

CCGTCTAGACACGCAACTTCCCGCTCGACTCCATATCCAATCACAATCAAG      51
ATG CCT GGC CAG CAA GCA ACC AAG CAT GAG TCC CTT TTG GAC CAG CTC      99
M  P  G  Q  Q  A  T  K  H  E  S  L  L  D  Q  L      16

TCC CTC AAG GGC AAG GTC GTC GTC GTC ACC GGC GCT TCC GGC CCC AAG      147
S  L  K  G  K  V  V  V  V  V  T  G  A  S  G  P  K      32

GGC ATG GGT AIT GAG GCC GCT CGC GGT TGC GCC GAG ATG GGC GCC GCT      195
G  M  G  I  E  A  A  R  G  C  A  E  M  G  A  A      48

GTT GCC ATC ACC TAC GCC TCC CGC GCC CAG GGT GCT CAG GAG AAC GTC      243
V  A  I  T  Y  A  S  R  A  Q  G  A  E  E  N  V      64

AAG GAG CTT GAG AAG ACC TAC GGC ATC AAG GCC AAG GCC TAC AAG TGC      291
K  E  L  E  K  T  Y  G  I  K  A  K  A  Y  K  C      80

CAG GTC GAC AGC TAC GAG TCC TGC GAG AAG CTC GTC AAG GAC GTC GTT      339
Q  V  D  S  Y  E  S  C  E  K  L  V  K  D  V  V      96

GCC GAC TTC GGC CAG ATC GAT GCC TTC ATC GCC AAG GCC GGT GCC ACC      387
A  D  F  G  Q  I  D  A  F  I  A  N  A  G  A  T      112

GCC GAC TCT GGC ATC CTC GAC GGC TCC GTC GAG GCC TGG AAC CAC GTC      435
A  D  S  G  I  L  D  G  S  V  E  A  W  N  H  V      128

GTC CAG GTC GAC CTC AAC GGT ACC TTC CAC TGC GCC AAG GCC GTT GGC      493
V  Q  V  D  L  N  G  T  F  H  C  A  K  A  V  G      144

CAC CAC TTC AAG GAG CGT GGA ACC GGT TCC CTC GTC ATC ACC GCC TCC      531
H  H  F  K  E  R  G  T  G  S  L  V  I  T  A  S      160

ATG TCC GGC CAC ATC GCC AAC TTC CCC CAG GAG CAG ACC TCC TAC AAC      579
M  S  G  H  I  A  N  F  P  Q  E  Q  T  S  Y  N      176

GTC GCC AAG GGT GGC TGC ATC CAC ATG GGT CGC TCC CTC GCC AAC GAG      627
V  A  K  A  G  C  I  H  M  A  R  S  L  A  N  E      192

TGG CGC GAC TTC GCC CGT GTC AAC TCC ATC TCC CCC GGT TAC ATT GAC      675
W  R  D  F  A  R  V  N  S  I  S  P  G  Y  I  D      208

ACT GGT CTC TCC GAC TTC GTT CCC AAG GAG ACC CAG CAG CTC TGG CAC      723
T  G  L  S  D  F  V  P  K  E  T  Q  Q  L  W  H      224

TCC ATG ATC CCC ATG GGC CGT GAC GGT CTC GCC AAG GAG CTC AAG GGC      771
S  M  I  P  M  G  R  D  G  L  A  K  E  L  K  G      240

GCC TAC GTC TAC TTC GCC TCC GAC GCC TCC ACC TAC ACC ACC GGT GCC      819
A  Y  V  Y  F  A  S  D  A  S  T  Y  T  T  G  A      256

GAT CTC CTC ATT GAC GGT GGT TAC ACC ACC AGA TAA      855
D  L  L  I  D  G  G  Y  T  T  R  *      268
GGGACTCGCCACAGCAAGTCGTTGAGGCGGAAGGACAAAAAAAAAAAAAAAAAAAAA      918

```

```

Met Pro Ile Thr Val Pro Gln Ala Thr Glu Leu Lys Asp Leu Phe Ser
 1          5          10          15
Leu Lys Gly Lys Val Val Ile Val Thr Gly Ala Ser Gly Pro Thr Gly
 20          25          30
Ile Gly Thr Glu Ala Ala Arg Gly Cys Ala Glu Tyr Gly Ala Asp Leu
 35          40          45
Ala Ile Thr Tyr Asn Ser Arg Ala Glu Gly Ala Glu Lys Asn Ala Lys
 50          55          60
Glu Met Ser Glu Lys Tyr Gly Val Lys Val Lys Ala Tyr Lys Cys Gln
 65          70          75          80
Val Asn Glu Tyr Ala Gln Cys Glu Lys Leu Val Gln Asp Val Ile Lys
 85          90          95
Asp Phe Gly Lys Val Asp Val Phe Ile Ala Asn Ala Gly Lys Thr Ala
100          105          110
Asp Asn Gly Ile Leu Asp Ala Thr Val Glu Gln Trp Asn Glu Val Ile
115          120          125
Gln Thr Asp Leu Thr Gly Thr Phe Asn Cys Ala Arg Ala Val Gly Leu
130          135          140
His Phe Arg Glu Arg Lys Thr Gly Ser Leu Val Ile Thr Ser Ser Met
145          150          155          160
Ser Gly His Ile Ala Asn Phe Pro Gln Glu Gln Ala Ser Tyr Asn Val
165          170          175
Ala Lys Ala Gly Cys Ile His Leu Ala Lys Ser Leu Ala Asn Glu Trp
180          185          190
Arg Asp Phe Ala Arg Val Asn Ser Ile Ser Pro Gly Tyr Ile Asp Thr
195          200          205
Gly Leu Ser Asp Phe Val Pro Gln Asp Ile Gln Lys Leu Trp His Ser
210          215          220
Met Ile Pro Met Gly Arg Asp Ala Lys Ala Thr Glu Leu Lys Gly Ala
225          230          235          240
Tyr Val Tyr Phe Ala Ser Asp Ala Ser Ser Tyr Cys Thr Gly Ser Asp
245          250          255
Leu Leu Ile Asp Gly Gly Tyr Cys Val Arg
260          265

```

Fig. 4: *Alternaria alternata* MtDH (Seq. ID No. 11)

*Alternaria alternata* MtDH

CTTCATATCACATCACACTTCAA	23
CTCAATTCGCCATTTTATATACGCCCAAACCTTCTTACTCTTCATAAACCCACATAATGCCACA	86
ATG CCC ATC ACC GTT CCC CAA GCT ACC GAG CTC AAG GAC CTC TTC AGC	134
M P I T V P Q A T E L K D L F S	16
CTT AAG GGC AAG GTC ATC GTC ACC GGT GCC TCC GGC CCC ACC GGT	182
L K G X V V I V T Q A S G P T G	32
ATT GGC ACA GAG GCT GCC CGA GGA TGC GCT GAG TAC GGT GCC GAC CTC	230
I G T E A A R G C A E Y G A D L	48
GCC ATC ACC TAC AAC TCT CGC GCC GAG GGT GCC GAG AAG AAC GCA AAG	278
A I T Y N S R A E G A E K N A K	64
GAG ATG AGC GAG AAG TAC GGC GTC AAG GTC AAG GCC TAC AAG TGC CAG	326
E M S E K Y G V K V K A Y K C Q	80
GTC AAC GAG TAC GCT CAG TGC GAG AAG CTC GTC CAG GAC GTC ATC AAG	374
V N E Y A Q C E K L V Q D V I K	96
GAC TTC GGC AAG GTC GAT GTC TTC ATC GCC AAC GCC GGA AAG ACT GCC	422
D F G K V D V F I A N A G K T A	112
GAC AAC GGT ATC CTC GAC GCT ACC GTT GAG CAG TGG AAC GAG GTC ATC	470
D N G I L D A T V E Q W N E V I	128
CAG ACC GAC TTG ACC GGT ACC TTC AAC TGC GCC CGT GCC GTT GGT CTC	518
Q T D L T G T F N C A R A V G L	144
CAC TTC CGC GAG CGC AAG ACT GGC TCT CTC GTC ATC ACC TCC TCC ATG	566
H F R E R K T G S L V I T S S M	160
TCC GGC CAC ATT GCC AAC TTC CCC CAG GAG CAG GCC TCC TAC AAC GTT	614
S G H I A N F P Q E Q A S Y N V	176
GCT AAG GCT GGC TGC ATT CAC CTC GCC AAG TCG CTC GCC AAC GAG TGG	662
A K A G C I H L A K S L A N E W	192
AGG GAC TTT GCC COT GTC AAC TCC ATC TCC COT GGA TAC ATT GAC ACT	710
R D F A R V N S I S P G Y I D T	208
GGT CTC TCC GAC TTC GTT CCC CAG GAC ATC CAG AAG CTG TGG CAC TCC	758
G L S D F V P Q D I Q K L W H S	224
ATG ATC CCC ATG GGC CGT GAC GCC AAG GCT ACT GAG CTC AAG GGT GCC	806
M I P M G R D A K A T E L K G A	240
TAC GTC TAC TTC GCA TCG GAT GCC TCA TCC TAC TGC ACT GGT TCC GAT	854
Y V Y F A S D A S S Y C T S S D	256
CTC CTC ATC GAC GGT GGT TAC TGC GTC AGG TAA	887
L L I D G G Y C V R *	267
ACGGTGTATTCCGAPAGGAGATGCGAGTGGAGGAATATAATAATGACGACCTCTTGCCCGA	950
AGTCTTTGTGTCATGTAAATAGCATCGAGACATCAATAAAGCTTCGCAGGTTTCACATCACAA	1013
AAAAAAAAAAAA	1026

5

Fig. 5: DNA sequence (seq. ID No. 12) of the *Alternaria alternata* mannitol dehydrogenase

```

C.herbarum      1  ATGCGCTGGCCAGCAAGCAAGCATGAGTCCCTTTGGACAGCTGCGCTGAGGGC
A.alternata     1  ATGCGC---ATGACCGTTCCGAGGCTACCGAGCTCAAGGACGCTGAGCGCTGAGGGC

C.herbarum      61  AAGGTGCTCGTCTGTCACCGCTGCTTCCGCCCCAAGGCGATGGGTATGAGGCGCGTGGC
A.alternata     58  AAGGTGCTCATCTGTCACCGCTGCTTCCGCCCCAAGGCGATGGGTATGAGGCGCGTGGC

C.herbarum      121  GGTGCGGCGAGATGGGCTCCGCTCTTCCATCACTACGCTTCCGCGCCAGGGTGGT
A.alternata     118  GGTGCGGCGAGATGGGCTCCGCTCTTCCATCACTACGCTTCCGCGCCAGGGTGGC

C.herbarum      181  GAGGAGAACCTCAGGAGCTTGAAGAGCTACGCCATCAAGCCCAAGGCTTACAGTGG
A.alternata     178  GAGGAGAACCTCAGGAGCTTGAAGAGCTACGCCATCAAGCCCAAGGCTTACAGTGG

C.herbarum      241  CAGGTGACAGCTACGAGTCCGCGAGAGTGGTCAAGGAGCTGGTACCGACTTCGGC
A.alternata     238  CAGGTGACAGCTACGAGTCCGCGAGAGTGGTCAAGGAGCTGGTACCGACTTCGGC

C.herbarum      301  CAGTCCGATGCTTTCATCGCCACGCGGCTCCAGCGCGAGCTCTGGCATCTCTGAGCGC
A.alternata     298  CAGTCCGATGCTTTCATCGCCACGCGGCTCCAGCGCGAGCTCTGGCATCTCTGAGCGC

C.herbarum      361  TCCGTGAGCGCTGAGAGCTCTGCTCCAGCTGAGCTGAGCGGTACCTTCGCTGCGCC
A.alternata     358  TCCGTGAGCGCTGAGAGCTCTGCTCCAGCTGAGCTGAGCGGTACCTTCGCTGCGCC

C.herbarum      421  AAGCGCGTTGCTCACCCTTCAGAGCTGAGAGCTGAGAGCTGCTGCTGATCAGCGCTCC
A.alternata     418  AAGCGCGTTGCTCACCCTTCAGAGCTGAGAGCTGAGAGCTGCTGCTGATCAGCGCTCC

C.herbarum      481  ATGTCGCGGCACATGCGCACTTCCCGCAGGAGCAGCTCTACAGCTGCGCAAGCGT
A.alternata     478  ATGTCGCGGCACATGCGCACTTCCCGCAGGAGCAGCTCTACAGCTGCGCAAGCGT

C.herbarum      541  GCGTGCATCCAGATGCGTCTGCTCTGCGCAACGAGTGGCGGACTTGCCTGCTCAAC
A.alternata     538  GCGTGCATCCAGATGCGTCTGCTCTGCGCAACGAGTGGCGGACTTGCCTGCTCAAC

C.herbarum      601  TCCATCTCCCGCTGCTTACATTCGACCTGGTCTCTCGGACTTGGTTCGCAAGGACACCGAG
A.alternata     598  TCCATCTCCCGCTGCTTACATTCGACCTGGTCTCTCGGACTTGGTTCGCAAGGACACCGAG

C.herbarum      661  CAGCTGCGGCACTCCATGATCCCGATGGGCGCTGAGCTCTGCGCAGGAGCTCAAGGGC
A.alternata     658  CAGCTGCGGCACTCCATGATCCCGATGGGCGCTGAGCTCTGCGCAGGAGCTCAAGGGC

C.herbarum      721  GCTACGCTCTACTTGGGCTGCGAGCTCTCAGCTACAGCAGCTGCGGATCTCTGATT
A.alternata     718  GCTACGCTCTACTTGGGCTGCGAGCTCTCAGCTACAGCAGCTGCGGATCTCTGATT

```

5 Fig. 6: Alignment of the C. herbarum and A. alternata DNA sequences

C.herbarum 781 GACGCTGGTTACACACAGATAA  
 A.alternata 778 GACCGTGGTTAC:CGCTCAGGTAA

C.herbarum 1 HECQATKEESLLQQLSLKGRVIVYTCASCHGKGLAARGQARQNAVAITNARAGT  
 A.alternata 1 HE-ITVPQATEERQLFLSLKGRVIVYTCASCHGKGLAARGQARQNAVAITNARAGT

C.herbarum 61 BETVNELEKAYGIRAKATKQVDSWESSEFLNKVVAQFGQIDARIANAGAPASGILDG  
 A.alternata 60 BRPAKESSEYQURVAYKQCVNEAQCERKQDVKQFGQVETANACQADNGILDA

C.herbarum 121 GVEARHEVVOVPLNGSTHFAKAVGHEHFGGGLVIDAASGSHIANFROGASVHVAKA  
 A.alternata 120 FVEARHEVVOVPLNGSTHFAKAVGHEHFGGGLVIDAASGSHIANFROGASVHVAKA

C.herbarum 181 GCINMARSLANEVRDFARVNSISPGYIDTGLSDQVPRSTQQLWHSHTFNGRDLAKELKQ  
 A.alternata 180 GCINMARSLANEVRDFARVNSISPGYIDTGLSDQVPRSTQQLWHSHTFNGRDLAKELKQ

C.herbarum 241 AYVYFASDASTVTPQDLITDGGYVTS  
 A.alternata 240 AYVYFASDASSYCTGSDLLIDGGYVTS

## SEQUENZPROTOKOLL

<110> Biomay Produktions- und Handels-Gesellschaft m.b.H

<120> Polypeptid kodierend für eine Mannit-Dehydrogenase,  
dessen Herstellung und Verwendung in Diagnostik und  
Therapie

<130> Cla h 1

<140>

<141>

<150> 102 14 082.0

<151> 2002-C3-28

<150> 102 33 676.8

<151> 2002-C7-24

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 173

<212> PRT

<213> Cladosporium herbarum

<400> 1

Leu Lys Gly Lys Val Val Val Val Thr Gly Ala Ser Gly Pro Lys Gly  
1 5 10 15

Met Gly Ile Glu Ala Ala Arg Gly Cys Ala Glu Met Gly Ala Ala Val  
20 25 30

Ala Ile Thr Tyr Ala Ser Arg Ala Gln Gly Ala Glu Glu Asn Val Lys  
35 40 45

Glu Leu Glu Lys Thr Tyr Gly Ile Lys Ala Lys Ala Tyr Lys Cys Gln  
50 55 60

Val Asp Ser Tyr Glu Ser Cys Glu Lys Leu Val Lys Asp Val Val Ala  
65 70 75 80

Asp Phe Gly Gln Ile Asp Ala Phe Ile Ala Asn Ala Gly Ala Thr Ala  
85 90 95

Asp Ser Gly Ile Leu Asp Gly Ser Val Glu Ala Trp Asn His Val Val  
1



100                      105                      110  
 Gln Val Asp Leu Asn Gly Thr Phe His Cys Ala Lys Ala Val Gly His  
 115                      120                      125  
 His Phe Lys Glu Arg Gly Thr Gly Ser Phe Val Ile Thr Ser Ser Met  
 130                      135                      140  
 Ser Gly His Ile Ala Asn Tyr Pro Gln Glu Gln Thr Ser Tyr Asn Val  
 145                      150                      155                      160  
 Ala Lys Ala Gly Cys Ile His Met Ala Arg Ser Leu Ala  
 165                      170

<210> 2  
 <211> 519  
 <212> DNA  
 <213> Cladosporium herbarum

<400> 2  
 ctgaaggga aggtcgtcgt cgttacggc gcttcgggc ccaagggcat gggatttgag 60  
 gccgctcgcg gttgcgcga gatggcgcc gctgttgcca tcacctacgc ctcccgcgc 120  
 cagggtgctg aggagaacgt caaggagctt gagaagacct acggcatcaa ggccaaggcc 180  
 tacaagtgcc aggtcgacag ctacgagtc tgcgagaagc tcgtcaagga cgtcgttgcc 240  
 gacttcggcc agatcgatgc ctccatcgcc aacgcgggtg ccaccgcgcg ctctggcatc 300  
 ctcgacggct ccgtcgaggc ctggaaccac gtcgtccagg tcgacctgaa cggtaacctc 360  
 cactgcgcca aggcggttgg ccaccacttc aaggagcgtg gaaccgggtc ctctgcatc 420  
 acctcttcca tctccggcca catcgccaac tatccccagg aacagacctc ctacaacgtc 480  
 gccaaaggct gatgcatcca catggctcgc tcttggca 519

<210> 3  
 <211> 266  
 <212> PRT  
 <213> Cladosporium fulvum

<400> 3  
 Met Pro Gln Arg Ile Pro Glu Ala Glu His Leu Leu Asp Leu Leu Ser  
 1                      5                      10                      15  
 Leu Lys Gly Arg Val Val Val Val Thr Gly Ala Ser Gly Pro Lys Gly  
 20                      25                      30  
 Met Gly Ile Glu Ala Ala Arg Gly Cys Ala Glu Met Gly Ala Asp Leu  
 35                      40                      45  
 Ala Ile Thr Tyr Ala Ser Arg Ala Glu Gly Gly Leu Lys Asn Ala Glu  
 2

50                      55                      60  
 Glu Leu Ser Lys Gln Tyr Gly Ile Lys Cys Lys Ala Tyr Lys Cys Gln  
 65                      70                      75                      80  
 Val Asp Lys Tyr Glu Ser Val Glu Gln Leu Val Lys Asp Val Ile Gln  
                     85                      90                      95  
 Asp Phe Gly Lys Ile Asp Ala Phe Ile Ala Asn Ala Gly Ala Thr Ala  
                     100                      105                      110  
 Asn Ser Gly Ile Leu Asp Gly Ser Val Glu Asp Trp Asn His Val Val  
                     115                      120                      125  
 Gln Val Asp Leu Asn Gly Thr Phe His Cys Ala Lys Ala Val Gly His  
                     130                      135                      140  
 His Phe Lys Glu Arg Gly Thr Gly Ser Phe Val Ile Thr Ser Ser Met  
 145                      150                      155                      160  
 Ser Gly His Ile Ala Asn Tyr Pro Gln Glu Gln Thr Ser Tyr Asn Val  
                     165                      170                      175  
 Ala Lys Ala Gly Cys Ile His Met Ala Arg Ser Leu Ala Asn Glu Trp  
                     180                      185                      190  
 Arg Asp Phe Ala Arg Val Asn Ser Ile Ser Pro Gly Tyr Ile Asp Thr  
                     195                      200                      205  
 Gly Leu Ser Asp Phe Val Ala Lys Asp Ile Gln Lys Leu Trp His Ser  
                     210                      215                      220  
 Met Ile Pro Leu Gly Arg Asp Gly Leu Ala Lys Glu Leu Lys Gly Ala  
 225                      230                      235                      240  
 Tyr Val Tyr Leu Val Ser Asp Ala Ser Thr Tyr Thr Thr Gly Ala Asp  
                     245                      250                      255  
 Ile Val Ile Asp Gly Gly Tyr Thr Cys Arg  
                     260                      265

&lt;210&gt; 4

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Cladosporium herbarum

&lt;400&gt; 4

Pro Gly Gln Gln Ala Thr Lys His Glu Ser Leu Leu Asp Gln Leu Ser  
 1 5 10 15

<210> 5  
 <211> 11  
 <212> PRT  
 <213> Cladosporium herbarum

<400> 5  
 Leu Asp Thr Gly Leu Ser Asp Phe Val Val Lys  
 1 5 10

<210> 6  
 <211> 10  
 <212> PRT  
 <213> Cladosporium herbarum

<400> 6  
 Met Gly Arg Asp Gly Leu Ala Lys Glu Leu  
 1 5 10

<210> 7  
 <211> 918  
 <212> DNA  
 <213> Cladosporium herbarum

<400> 7  
 ccgctctacac acgcaacttc ccgcctcgac tccatatcca atcacatcaa gatgcctggc 60  
 cagcaagcaa ccaagcatga gtcccttttg gaccagctct cctgaaggg caaggtcgtc 120  
 gtctgcaccg gcgtctccgg ccccaagggc atgggtatcg aggccgctcg cggttgcgcc 180  
 gagatgggag ccgtgtttgc calcacctac gcctcccgcg cccagggtgc tgaggagaa 240  
 gtcaaggagc ttgagaagac ctacggcctc aaggccaagg cctacaagtg ccaggtcgac 300  
 agctacgagt cctgcgagaa gctcgtcaag gacgtcgttg ccgacttcgg ccagatcgat 360  
 gccttcctcg ccaacgcggg tgccaccgcc gactctggca tctcgacgg ctccgtcgag 420  
 gcctggaacc acgtcgtcca ggtcgacctg aacggtaact tccactgcgc caaggccgtt 480  
 ggccaccact tcaaggagcg tggaaaccgt tccctcgtca tcaccgecte catgtccggc 540  
 cacatcgcca acttcccca ggagcagacc tctacaacg tcgccaaggc tggctgcctc 600  
 cacatggctc gctccctcgc caacgagtg ggcgaacttc cccgtgtcaa ctccatctcc 660  
 cccggttaca ttgacactgg tctctccgac ttctgttcca aggagaccca gcagctctgg 720  
 cactccatga tcccatggg ccgtgacggt ctgcccaagg agctcaagg gcctacgtc 780  
 tacttcgct ccgacgcctc caccacacc accggtgccg atctcctcat tgacgggtgg 840  
 tacaccacca gataagccac tcgccacag caagtctgtg aggcggaagg aaaaaaaaa 900  
 aaaaaaaaa aaaaaaaaa 918

<210> 8  
 <211> 267  
 <212> PRT  
 <213> Cladosporium herbarum  
  
 <400> 8  
 Met Pro Gly Gln Gln Ala Thr Lys His Glu Ser Leu Leu Asp Gln Leu  
     1                    5                    10                    15  
  
 Ser Leu Lys Gly Lys Val Val Val Val Thr Gly Ala Ser Gly Pro Lys  
             20                    25                    30  
  
 Gly Met Gly Ile Glu Ala Ala Arg Gly Cys Ala Glu Met Gly Ala Ala  
             35                    40                    45  
  
 Val Ala Ile Thr Tyr Ala Ser Arg Ala Gln Gly Ala Glu Glu Asn Val  
             50                    55                    60  
  
 Lys Glu Leu Glu Lys Thr Tyr Gly Ile Lys Ala Lys Ala Tyr Lys Cys  
             65                    70                    75                    80  
  
 Gln Val Asp Ser Tyr Glu Ser Cys Glu Lys Leu Val Lys Asp Val Val  
                     85                    90                    95  
  
 Ala Asp Phe Gly Gln Ile Asp Ala Phe Ile Ala Asn Ala Gly Ala Thr  
                     100                    105                    110  
  
 Ala Asp Ser Gly Ile Leu Asp Gly Ser Val Glu Ala Trp Asn His Val  
             115                    120                    125  
  
 Val Gln Val Asp Leu Asn Gly Thr Phe His Cys Ala Lys Ala Val Gly  
             130                    135                    140  
  
 His His Phe Lys Glu Arg Gly Thr Gly Ser Leu Val Ile Thr Ala Ser  
     145                    150                    155                    160  
  
 Met Ser Gly His Ile Ala Asn Phe Pro Gln Glu Gln Thr Ser Tyr Asn  
                     165                    170                    175  
  
 Val Ala Lys Ala Gly Cys Ile His Met Ala Arg Ser Leu Ala Asn Glu  
             180                    185                    190  
  
 Trp Arg Asp Phe Ala Arg Val Asn Ser Ile Ser Pro Gly Tyr Ile Asp  
             195                    200                    205  
  
 Thr Gly Leu Ser Asp Phe Val Pro Lys Glu Thr Gln Gln Leu Trp His  
             210                    215                    220

WO 03/083098

PCT/EP03/02873

Ser Met Ile Pro Met Gly Arg Asp Gly Leu Ala Lys Glu Leu Lys Gly  
225 230 235 240

Ala Tyr Val Tyr Phe Ala Ser Asp Ala Ser Thr Tyr Thr Thr Gly Ala  
245 250 255

Asp Leu Leu Ile Asp Gly Gly Tyr Thr Thr Arg  
260 265

<210> 9

<211> 266

<212> PRT

<213> Cladosporium fulvum

<400> 9

Met Pro Gln Arg Ile Pro Glu Ala Glu His Leu Leu Asp Leu Leu Ser  
1 5 10 15

Leu Lys Gly Arg Val Val Val Val Thr Gly Ala Ser Gly Pro Lys Gly  
20 25 30

Met Gly Ile Glu Ala Ala Arg Gly Cys Ala Glu Met Gly Ala Asp Leu  
35 40 45

Ala Ile Thr Tyr Ala Ser Arg Ala Glu Gly Gly Leu Lys Asn Ala Glu  
50 55 60

Glu Leu Ser Lys Gln Tyr Gly Ile Lys Cys Lys Ala Tyr Lys Cys Gln  
65 70 75 80

Val Asp Lys Tyr Glu Ser Val Glu Gln Leu Val Lys Asp Val Ile Gln  
85 90 95

Asp Phe Gly Lys Ile Asp Ala Phe Ile Ala Asn Ala Gly Ala Thr Ala  
100 105 110

Asn Ser Gly Ile Leu Asp Gly Ser Val Glu Asp Trp Asn His Val Val  
115 120 125

Gln Val Asp Leu Asn Gly Thr Phe His Cys Ala Lys Ala Val Gly His  
130 135 140

His Phe Lys Glu Arg Gly Thr Gly Ser Phe Val Ile Thr Ser Ser Met  
145 150 155 160

Ser Gly His Ile Ala Asn Tyr Pro Gln Glu Gln Thr Ser Tyr Asn Val  
165 170 175

6

Ala Lys Ala Gly Cys Ile His Met Ala Arg Ser Leu Ala Asn Glu Trp  
 180 185 190

Arg Asp Phe Ala Arg Val Asn Ser Ile Ser Pro Gly Tyr Ile Asp Thr  
 195 200 205

Gly Leu Ser Asp Phe Val Ala Lys Asp Ile Gln Lys Leu Trp His Ser  
 210 215 220

Met Ile Pro Leu Gly Arg Asp Gly Leu Ala Lys Glu Leu Lys Gly Ala  
 225 230 235 240

Tyr Val Tyr Leu Val Ser Asp Ala Ser Thr Tyr Thr Thr Gly Ala Asp  
 245 250 255

Ile Val Ile Asp Gly Gly Tyr Thr Cys Arg  
 260 265

<210> 10  
 <211> 267  
 <212> PRT  
 <213> Cladosporium herbarum

<400> 10  
 Met Pro Gly Gln Gln Ala Thr Lys His Glu Ser Leu Leu Asp Gln Leu  
 1 5 10 15

Ser Leu Lys Gly Lys Val Val Val Val Thr Gly Ala Ser Gly Pro Lys  
 20 25 30

Gly Met Gly Ile Glu Ala Ala Arg Gly Cys Ala Glu Met Gly Ala Ala  
 35 40 45

Val Ala Ile Thr Tyr Ala Ser Arg Ala Gln Gly Ala Glu Glu Asn Val  
 50 55 60

Lys Glu Leu Glu Lys Thr Tyr Gly Ile Lys Ala Lys Ala Tyr Lys Cys  
 65 70 75 80

Gln Val Asp Ser Tyr Glu Ser Cys Glu Lys Leu Val Lys Asp Val Val  
 85 90 95

Ala Asp Phe Gly Gln Ile Asp Ala Phe Ile Ala Asn Ala Gly Ala Thr  
 100 105 110

Ala Asp Ser Gly Ile Leu Asp Gly Ser Val Glu Ala Trp Asn His Val

115                      120                      125  
 Val Gln Val Asp Leu Asn Gly Thr Phe His Cys Ala Lys Ala Val Gly  
 130                      135                      140  
 His His Phe Lys Glu Arg Gly Thr Gly Ser Leu Val Ile Thr Ala Ser  
 145                      150                      155                      160  
 Met Ser Gly His Ile Ala Asn Phe Pro Gln Glu Gln Thr Ser Tyr Asn  
 165                      170                      175  
 Val Ala Lys Ala Gly Cys Ile His Met Ala Arg Ser Leu Ala Asn Glu  
 180                      185                      190  
 Trp Arg Asp Phe Ala Arg Val Asn Ser Ile Ser Pro Gly Tyr Ile Asp  
 195                      200                      205  
 Thr Gly Leu Ser Asp Phe Val Pro Lys Glu Thr Gln Gln Leu Trp His  
 210                      215                      220  
 Ser Met Ile Pro Met Gly Arg Asp Gly Leu Ala Lys Glu Leu Lys Gly  
 225                      230                      235                      240  
 Ala Tyr Val Tyr Phe Ala Ser Asp Ala Ser Thr Tyr Thr Thr Gly Ala  
 245                      250                      255  
 Asp Leu Leu Ile Asp Gly Gly Tyr Thr Thr Arg  
 260                      265

&lt;210&gt; 11

&lt;211&gt; 266

&lt;212&gt; PRT

<213> *Alternaria alternata*

&lt;400&gt; 11

Met Pro Ile Thr Val Pro Gln Ala Thr Glu Leu Lys Asp Leu Phe Ser  
 1                      5                      10                      15  
 Leu Lys Gly Lys Val Val Ile Val Thr Gly Ala Ser Gly Pro Thr Gly  
 20                      25                      30  
 Ile Gly Thr Glu Ala Ala Arg Gly Cys Ala Glu Tyr Gly Ala Asp Leu  
 35                      40                      45  
 Ala Ile Thr Tyr Asn Ser Arg Ala Glu Gly Ala Glu Lys Asn Ala Lys  
 50                      55                      60

WO 03/083098

PCT/EP03/02873

Glu Met Ser Glu Lys Tyr Gly Val Lys Val Lys Ala Tyr Lys Cys Gln  
65 70 75 80

Val Asn Glu Tyr Ala Gln Cys Glu Lys Leu Val Gln Asp Val Ile Lys  
85 90 95

Asp Phe Gly Lys Val Asp Val Phe Ile Ala Asn Ala Gly Lys Thr Ala  
100 105 110

Asp Asn Gly Ile Leu Asp Ala Thr Val Glu Gln Trp Asn Glu Val Ile  
115 120 125

Gln Thr Asp Leu Thr Gly Thr Phe Asn Cys Ala Arg Ala Val Gly Leu  
130 135 140

His Phe Arg Glu Arg Lys Thr Gly Ser Leu Val Ile Thr Ser Ser Met  
145 150 155 160

Ser Gly His Ile Ala Asn Phe Pro Gln Glu Gln Ala Ser Tyr Asn Val  
165 170 175

Ala Lys Ala Gly Cys Ile His Leu Ala Lys Ser Leu Ala Asn Glu Trp  
180 185 190

Arg Asp Phe Ala Arg Val Asn Ser Ile Ser Pro Gly Tyr Ile Asp Thr  
195 200 205

Gly Leu Ser Asp Phe Val Pro Gln Asp Ile Gln Lys Leu Trp His Ser  
210 215 220

Met Ile Pro Met Gly Arg Asp Ala Lys Ala Thr Glu Leu Lys Gly Ala  
225 230 235 240

Tyr Val Tyr Phe Ala Ser Asp Ala Ser Ser Tyr Cys Thr Gly Ser Asp  
245 250 255

Leu Leu Ile Asp Gly Gly Tyr Cys Val Arg  
260 265

<210> 12

<211> 1026

<212> DNA

<213> *Alternaria alternata*

<400> 12

cttcatatca catcacactt caactcaatt cccatittat ataccocaaa cttctttact 60  
cttcataaac ccacataatc gccacaatgc ccatcaccgt toccaagct accgagctca 120



```

aggacctctt cagccttaag ggcaagggtcg tcctcgtcac cggcgccctcc ggccccaccg 180
gtattggcac agaggctgcc cgaggatgcg ctgagtaagg tgccgacctc gccatcacct 240
acaactctcg cggcgagggt gccgagaaga acgcaaagga gatgagcgag aagtaaggcg 300
tcaaggtaaa ggccatacaag tgccaggtaa acgagtaagg taagtgcgag aagctcgtcc 360
aggacgtcat caaggacttc ggcaagggtcg atgtcttcac cgcacaacgcc ggaaagactg 420
ccgacaacgg tatcctcgac gctaccgttg agcagtgga cagagtcata cagaccgact 480
tgaccggta cttcaactgc gcccggtgcc ttggtctcca cttccgcgag cgcaagactg 540
gctctctcgt catcacctcc tccatgtccg gccacattgc caacttcccc caggagcagg 600
cctcctacaa cgttgctaag gctgggtgca ttcacctcgc caagtcgctc gccaacgagt 660
ggagggactt tgcccgtgtc aactccatct cccctggata cattgacact ggtctctccg 720
acttcgttcc ccaggacatc cagaagctgt ggcactccat gatcccatg gcccgtagcg 780
ccaaggctac tgagctcaag ggtgcctacg tctacttcgc atcggatgcc tcactctact 840
gcactggttc cgtctctctc atcgacggtg gttactgcgt caggtaaacg tgtcattccg 900
gaaggagat gccagtgagg gaatataata atggacgacg tcttgccgga agtcttgtgt 960
ccatgtaaat agcatcgaga catcaalaaa gcttcgcagg ttccacatca caaaaaaaaa 1020
aaaaaa 1026

```